Covid-19
Britain investigates AstraZeneca-Alexion deal on competition concerns
Britain’s Competition and Markets Authority (CMA) has started its investigation into whether AstraZeneca’s takeover of Alexion Pharmaceuticals can reduce competition for products and services in the United Kingdom or any other markets.
The British competition regulator invites comments on the transaction from any interested party to assist the CMA with the assessment.
The comments should be reached by June 3.
In December 2020, British drug manufacturer AstraZeneca agreed to buy Alexion Pharmaceuticals for 175 dollars per share in cash and stock, valuing the Boston-based company at 39 billion dollars.
-
Featured6 days agoRanking the seven greatest World Cup finals of all time
-
Business1 week agoOPay breaks silence on viral September shutdown claim
-
Latest1 week agoTinubu’s FBI records: Omokri challenges claims, cites 2003 Embassy reply
-
Latest2 days agoCole-Alegbe unveils memoir, urges leaders to harness technology for lasting impact
-
Business5 days agoX3M Ideas donates 50 Walkie-Talkies to strengthen security operations in Onigbongbo
-
Latest6 days ago2027: Atiku vows direct payment of local government funds if elected president
-
Latest6 days ago2027: Atiku, Obi absent as opposition begins talks on single presidential candidate
-
Latest1 week agoAnambra 2027: INEC, NDC clash over 10 disputed Assembly candidates